山东大学学报(医学版) ›› 2017, Vol. 55 ›› Issue (1): 33-38.doi: 10.6040/j.issn.1671-7554.0.2016.1304
陆衡,刘延国,李曙光,陈晓康,田琦,衣翠华,王秀问
LU Heng, LIU Yanguo, LI Shuguang, CHEN Xiaokang, TIAN Qi, YI Cuihua, WANG Xiuwen
摘要: 目的 探讨YKL-40对卵巢癌SKOV-3细胞体外迁移能力的影响。 方法 采用RT-PCR检测卵巢癌SKOV-3细胞YKL-40 mRNA水平的表达;采用慢病毒感染的方法在SKOV-3细胞过表达YKL-40,qRT-PCR、ELISA、Western blotting验证YKL-40的过表达;Transwell实验检测YKL-40过表达对SKOV-3细胞迁移能力的影响;特异性抑制剂抑制YKL-40过表达SKOV-3细胞中的p38 MAPK通路,检测其对细胞迁移能力的影响。 结果 SKOV-3细胞中未检测到YKL-40 mRNA的表达;成功构建了YKL-40过表达细胞株LV-SKOV-3,感染率达90%以上;与空载体慢病毒感染的对照SKOV-3细胞(NC-SKOV-3)相比,LV-SKOV-3细胞YKL-40无论mRNA表达还是蛋白水平(细胞总蛋白、分泌蛋白)均明显上调;Transwell细胞迁移实验表明过表达YKL-40的LV-SKOV-3细胞较空载体对照细胞NC-SKOV-3迁移能力显著增强,而通过SB203580抑制p38 MAPK通路p38蛋白磷酸化后,LV-SKOV-3细胞的迁移能力明显下调。 结论 YKL-40可显著促进卵巢癌SKOV-3细胞的迁移,这一作用可能是通过p38 MAPK通路介导的。
中图分类号:
| [1] 李燕, 尉蔚, 吕树卿, 等. PARP-1对卵巢癌血管生成的影响[J].山东大学学报(医学版), 2014, 52(4):97-106. LI Yan, WEI Wei, L(¨overU)Shuqing, et al. Effects of PARP-1 on angiogenesis of ovarian cancer[J]. Journal of Shandong University(Health Science), 2014, 52(4):97-106. [2] Lengyel E. Ovarian cancer development and metastasis[J]. Am J Pathol, 2010, 177(3):1053-1064. [3] Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients?[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(2):194-202. [4] Jefri M, Huang YN, Huang WC, et al. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer[J]. BMC Cancer, 2015, 15:590. doi:10.1186/s12885-015-1592-3. [5] Thongsom S, Chaocharoen W, Silsirivanit A, et al. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma[J]. Tumour Biol, 2016, 37(7):9451-9463. [6] Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors[J]. Genes & Cancer, 2013, 4(9-10):342-359. [7] Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3):183-203. [8] Ohno M, Bauer PO, Kida Y, et al. Quantitative real-time PCR analysis of YKL-40 and its comparison with mammalian chitinase mRNAs in normal human tissues using a single standard DNA [J]. Int J Mol Sci, 2015, 16(5):9922-9935. [9] Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases[J]. Curr Opin Allergy Clin Immunol, 2009, 9(5):401-408. [10] Kawada M, Seno H, Kanda K, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer[J]. Oncogene, 2012, 31(26):3111-3123. [11] Zou L, He X, Zhang JW. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer[J]. Braz J Med Biol Res, 2010, 43(12):1232-1238. [12] Kzhyshkowska J, Yin S, Liu T, et al. Role of chitinase-like proteins in cancer[J]. Biol Chem, 2016, 397(3):231-247. [13] Boisen MK, Madsen CV, Dehlendorff C, et al. The prognostic value of plasma YKL-40 in patients with chemotherapy-resistant ovarian cancer treated with Bevacizumab[J]. Int J Gynecol Cancer, 2016, 26(8):1390-1398. [14] Hogdall EV, Ringsholt M, Hogdall CK, et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer[J]. BMC Cancer, 2009, 9:8. doi:10.1186/1471-2407-9-8. [15] Low D, Subramaniam R, Lin L, et al. Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9 [J]. Oncotarget, 2015, 6(34):36535-36550. [16] Chiang YC, Lin HW, Chang CF, et al. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma [J]. Oncotarget, 2015, 6(37):39740-39755. [17] Abd El-Fattah AA, Sadik NA, Shaker OG, et al. Are SMAD7 rs4939827 and CHI3L1 rs4950928 polymorphisms associated with colorectal cancer in Egyptian patients? [J]. Tumour Biol, 2016, 37(7):9387-9397. [18] Ku BM, Lee YK, Ryu J, et al. CHI3L1(YKL-40)is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells [J]. Int J Cancer, 2011,128(6):1316-1326. [19] Li LL, Fan JT, Li DH, et al. Effects of a small interfering RNA targeting YKL-40 gene on the proliferation and invasion of endometrial cancer HEC-1A cells[J]. Int J Gynecol Cancer, 2016, 26(7):1190-1195. [20] Hsia TC, Yu CC, Hsiao YT, et al. Cantharidin impairs cell migration and invasion of human lung cancer NCI-H460 cells via UPA and MAPK signaling pathways[J]. Anticancer Res, 2016, 36(11):5989-5997. [21] Cheng HH, Chu LY, Chiang LY, et al. Inhibition of cancer cell epithelial mesenchymal transition by normal fibroblasts via production of 5-methoxytryptophan[J]. Oncotarget, 2016, 7(21):31243-31256. [22] Wang J, Cui L, Feng L, et al. Isoalantolactone inhibits the migration and invasion of human breast cancer MDA-MB-231 cells via suppression of the p38 MAPK/NF-kappaB signaling pathway[J]. Oncology Reports, 2016, 36(3):1269-1276. [23] Zhao W, Lu M, Zhang Q. Chloride intracellular channel 1 regulates migration and invasion in gastric cancer by triggering the ROS-mediated p38 MAPK signaling [J]. Mol Med Rep, 2015, 12(6):8041-8047. |
| [1] | 袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107. |
| [2] | 何静,严如根,武志红,李长忠. 消癥抑癌方对卵巢癌SKOV3细胞增殖、迁移的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 1-10. |
| [3] | 焦光丽,石子馨,陈蓉,宋亚博,杨飞,崔书君. 基于增强CT影像组学预测卵巢癌患者铂类药物敏感性[J]. 山东大学学报 (医学版), 2023, 61(12): 62-69. |
| [4] | 张艺馨,赵玉立,封丽. 超声特征及术前CA-125联合对51例卵巢交界性及Ⅰ期恶性肿瘤的鉴别诊断[J]. 山东大学学报 (医学版), 2022, 60(7): 104-109. |
| [5] | 哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123. |
| [6] | 陈君宇, 曹冬焱. 以脑梗为首发的卵巢癌病例报告[J]. 山东大学学报 (医学版), 2021, 59(5): 110-112. |
| [7] | 杨佳,张曼,陈凯明,曹曦. miR-146a经TLR4/MyD88途径加速巨噬细胞迁移所致动脉硬化的作用机制[J]. 山东大学学报 (医学版), 2021, 59(11): 1-7. |
| [8] | 王正阳,夏艳,师凯旋,陶琨,王小杰. 曲美替尼在卵巢癌中对PAX8的表达作用[J]. 山东大学学报 (医学版), 2021, 59(10): 25-31. |
| [9] | 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32-37. |
| [10] | 王宝金,赵欣欣,李霞,马倩,王新月,孙阳,史中娜. miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭[J]. 山东大学学报 (医学版), 2020, 58(12): 23-28. |
| [11] | 娄福臣,刘性祥,马国云,庄向华. 阿卡波糖对冠心病合并糖耐量受损患者YKL-40和肠道菌群的影响[J]. 山东大学学报 (医学版), 2019, 57(7): 86-91. |
| [12] | 刘崇东,娄彤,董靖. 子宫内膜异位症恶变[J]. 山东大学学报 (医学版), 2019, 57(6): 27-32. |
| [13] | 关红卫,李娟,孙锐,刘婕,李长忠. 乌苯美司对卵巢癌A2780细胞的生物学影响[J]. 山东大学学报 (医学版), 2019, 57(12): 46-51. |
| [14] | 朱爱国,马振敕,王健. 利用上皮源性卵巢癌预后的多基因信息建立预测预后模型[J]. 山东大学学报 (医学版), 2019, 57(10): 80-85. |
| [15] | 杨佳欣,沈铿,王遥. 妇科恶性肿瘤保留生育功能治疗的现状与展望[J]. 山东大学学报 (医学版), 2018, 56(5): 1-7. |
|
||